Welcome to THAC – The Healthy Aging Company
At THAC, we are dedicated to revolutionizing the treatment of diabetes and its neurologic and neurodegenerative complications and other age-related conditions through cutting-edge innovation.
Our Mission
Our mission is to develop game-changing therapies that address unmet medical needs and improve the lives of millions worldwide.
The Problem
Tackling the Global Epidemic of Diabetes and Aging, including Diabetes Neuropathy, Neurodegenerative Disorders and Age-Related Diseases
As society ages, age-related diseases are reaching epidemic proportions, posing immense challenges to healthcare systems and economics worldwide:
90%
of older adults have at least one chronic condition, nearly 80% have two or more
Global Health Crisis
Conditions such as cardiovascular disease, obesity, diabetes, and Alzheimer’s are now global health crises
80%
Age related diseases represent 80% of the US Medicare budget
$30 trillion
Age-related diseases are projected to cost over $30 trillion over the next 20 years
Diabetes and Diabetes-associated complications are major drivers of aging related diseases.
Despite major improvement in the treatment of Diabetes type II with GLP1 Receptor Agonists, diabetic neuropathy and diabetes-associated cognitive disorders and Alzheimer’s disease are still major unmet medical needs.
« At THAC, we are committed to addressing these challenges head-on with innovative therapies designed to improve lives and transform healthcare for a healthier, more sustainable future ».
Leveraging our expertise in biopharmaceutical research, we focus on:
Type 2 Diabetes Mellitus (T2DM) and associated complications
Diabetic Neuropathy
Cognitive disorders and Alzheimer’s Disease
Other conditions associated with aging
Our Solution: ALF-5755 – A Breakthrough Therapy
At THAC, we are leading the charge with ALF-5755, an innovative therapy designed to directly target the root causes of age-related diseases, offering hope for millions:
Directly targets insulin resistance
By addressing the core driver of Type 2 Diabetes and metabolic disorders.
Anti-inflammatory action
By reducing systemic inflammation associated with chronic conditions.
Reduces fat mass and triglycerides
By supporting healthier weight and metabolic balance.
Stimulates glucose uptake in muscle
By improving glycemic control and energy utilization.
Reduces diabetic neuropathy
By alleviating complications like diabetic foot wounds and preventing amputations.
Limits sarcopenia
By preserving muscle mass and strength in aging individuals.
Improves cognition
By targeting neurodegeneration to combat Alzheimer’s disease.
With ALF-5755, we are transforming the way age-related diseases are treated, improving patient outcomes, and redefining the future of healthcare.
THAC is a resident at the University of South Florida Research Innovation Park (US)
Registered in Delaware
Founded in Paris, France in partnership with Inserm and Universite Paris Cite.
